StockWatch
·

Windlas Biotech Ltd

BSE: 543329

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
267.77
+5.7%+18.5%
Expenditure
244.47
+6.2%+20.8%
Net Profit
18.05
+2.3%+1.4%
OPM %
11.13%
+0.38pp-1.71pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.0074.98149.95224.93299.90Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Windlas Biotech: revenue +18.7% YoY, margin squeeze caps PAT growth at 1.4%

pharmaceuticals · cdmo · margin compression

ResultsQ2 FY2705 Nov 20263 minPharma & Healthcare

Record revenue, flat profit—the ESOP mask and the Plant 6 pivot

CDMO · Trade Generics · Plant 6

Result verdictFollow-upQ1 FY2717 Aug 20266 minPharma & Healthcare

Record revenue, flat profit; Plant 6 catalyst ahead

14 consecutive quarters · CDMO 29% growth · TGx stagnant

TranscriptDeep diveQ1 FY2717 Aug 20266 minPharma & Healthcare
Latest
Board Meeting5 Nov, 4:20 pm

Windlas Biotech: revenue +18.7% YoY, margin squeeze caps PAT growth at 1.4%

Windlas Biotech's standalone revenue grew 18.7% YoY to ₹263.9 Cr in Q2 FY27 (quarter ended 30-Sep-2026), extending its growth run from ₹222.4 Cr a year ago, and rose 6.4% sequentially from ₹248.1 Cr in Q1 FY27. Profit after tax grew just 1.4% YoY to ₹18.05 Cr (₹17.80 Cr a year ago) and 2.3% QoQ (₹17.65 Cr) — profit growth trailing revenue growth by a wide margin, which is the core story of the quarter. Neither period carries exceptional items, so the gap is a genuine margin effect rather than a base-effect distortion. No Q2 FY27-specific street estimates for Windlas turned up in a search, so the print cannot be graded against consensus this quarter (vsStreet: unknown). Operating margin (EBITDA/revenue) came in near 11.1%, down from 12.8% a year ago though up slightly from 10.75% in Q1 FY27; net margin was 6.8%, down from 7.9% YoY and roughly flat sequentially (7.0%) — margin compression is a YoY phenomenon, not a QoQ one. Basic EPS of ₹8.75 rose 3.2% YoY and 3.4% QoQ, outpacing PAT growth, because the share count fell roughly 2.2% after the company completed a ₹47 Cr tender-offer buyback of 470,000 shares this half, on top of a ₹130 Cr FY26 dividend payout; both calls on cash were funded partly by a ₹16.4 Cr rise in short-term borrowings (₹29.9 Cr to ₹46.2 Cr). Management had guided on the Q1 FY27 call that Plant 6 would commercialize by the end of H1 FY27 — i.e., by this quarter-end — adding capacity toward ₹1,100 Cr of revenue. This filing does not name Plant 6 directly, but the balance sheet is consistent with that timeline: capital work-in-progress fell to nil from ₹56.2 Cr as of March 2026, while property, plant & equipment rose ₹29 Cr and right-of-use assets rose ₹35 Cr — a capitalization pattern that lines up with a facility going live in the exact window management flagged. No management press release accompanied this filing, so there is no fresh management commentary to check the numbers against this quarter. Separately, the same board meeting approved a leadership transition — Ashok Kumar Windlass stepped down as Whole-time Director as part of long-term succession planning, continuing as Senior Management Personnel/Founder President, while Hitesh Windlass was appointed Chairman — and the company had disclosed a cybersecurity incident on 30-Oct-2026, five days before results, with no financial impact quantified anywhere in this statement.

5 Nov 2026, 04:20 pm

Corporate Events

Board MeetingWINDLAS
2026
5Nov

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingWINDLAS
2026
10Aug

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingWINDLAS
2026
23Jul

Board Meeting

The 25th Annual General Meeting (AGM) of the Company is sche…

BSE Filing ↗
DividendWINDLAS
2026
16Jul

₹6.3 / share

BSE Filing ↗
Board MeetingWINDLAS
2026
21May

Board Meeting

The board meeting is scheduled to consider and approve the a…

BSE Filing ↗
Board MeetingWINDLAS
2025
12Aug

Board Meeting

Consider and approve Notice of the Board Meeting, un-audited…

BSE Filing ↗
DividendWINDLAS
2025
21Jul

₹5.8 / share

BSE Filing ↗
DividendWINDLAS
2024
31May

₹5.5 / share

BSE Filing ↗
DividendWINDLAS
2024
21May

₹5.5 / share

BSE Filing ↗
Board MeetingWINDLAS
2024
20May

Board Meeting

Consider and approve the audited standalone and consolidated…

BSE Filing ↗
Board MeetingWINDLAS
2024
8Feb

Board Meeting

Consider and approve un-audited standalone and consolidated …

BSE Filing ↗
Board MeetingWINDLAS
2023
8Nov

Board Meeting

Consider and approve the un-audited standalone and consolida…

BSE Filing ↗
Board MeetingWINDLAS
2023
8Aug

Board Meeting

Consider and approve un-audited standalone and consolidated …

BSE Filing ↗